023910 — DaehanPharmaceutical Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeSmall CapSuper Stock

Annual cashflow statement for DaehanPharmaceutical, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	28,167	17,381	22,670	24,961	28,426
Depreciation
Amortisation
Non-Cash Items	9,656	16,418	10,392	11,572	12,241
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-13,336	-11,472	-3,856	-16,740	-10,471
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	35,264	33,627	40,617	28,999	38,860
Capital Expenditures	-17,305	-5,360	-11,850	-8,621	-21,280
Purchase of Fixed Assets
Other Investing Cash Flow Items	-3,472	-5,577	336	8,815	3,283
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-20,777	-10,938	-11,515	193	-17,998
Financing Cash Flow Items	-1,819	-110	-61.7	—	-80
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-10,278	-5,709	-7,408	-22,543	-10,332
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	4,330	16,562	22,367	7,092	10,644